S&C Advises Impax Laboratories, Inc. in Completed Acquisition of Generic Products from Teva Pharmaceutical Industries Ltd. and Affiliates of Allergan plc

August 3, 2016

S&C client Impax Laboratories, Inc., a leading specialty pharmaceutical company, completed its previously announced acquisition of a broad portfolio of generic products across solid oral, inhalable, injectable and topical dosage forms from Teva Pharmaceutical Industries Ltd. and certain affiliates of Allergan plc for a purchase price of $586 million.

As part of the acquisition, Impax also received all of the rights to the pending abbreviated new drug application for the generic equivalent to Concerta® (methylphenidate hydrochloride). In connection with the asset purchase, Impax entered into supply agreements with Teva and certain affiliates of Allergan in which Teva and such affiliates of Allergan will supply certain generic marketed and pipeline pharmaceutical products to Impax.

Mr. Aquila and Mr. Hurd advised on corporate matters. Mr. Creamer advised on tax matters, and Mr. Blaut advised on financing matters.